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1. Introduction 
Targeted viral vector-mediated gene transfer to specific population of neurons in the central 
nervous system (CNS) is a relatively novel, but fast developing approach to study gene 
function in a number of neurodegenerative diseases (reviewed in Korecka, Verhaagen, & 
Hol, 2007; Manfredsson & Mandel, 2010). Moreover, several early phase clinical trials based 
on viral vector-mediated therapeutic gene transfer have been completed or are underway 
for neurological disorders (Kaplitt et al., 2007; reviewed in Korecka et al., 2007; Marks, Jr. et 
al., 2010; Muramatsu et al., 2010; Tuszynski et al., 2005). Gene therapy is especially attractive 
for diseases where neuronal degeneration is largely restricted to a single neuronal 
population in a specific anatomical area. Parkinson disease (PD) is a neurodegenerative 
disease mainly characterized by a progressive degeneration of dopaminergic (DAergic) 
neurons in the Substantia Nigra (SN) (Dauer & Przedborski, 2003). It would be desirable to 
direct transgene expression to the dopaminergic neurons in animal models for 
neurodegenerative diseases, allowing for a range of investigations into the function of that 
gene in normal, adult DAergic neurons or following neurotoxic insult.  
Lentiviral vectors (LV) and adeno-associated viral vectors (AAV) are increasingly regarded 
as the two most useful gene therapy vectors for the CNS. Both vectors have been 
successfully used to express a foreign gene in a variety of brain regions and neuronal cell 
types (Lim, Airavaara, & Harvey, 2010; Manfredsson & Mandel, 2010; Papale, Cerovic, & 
Brambilla, 2009; Schneider, Zufferey, & Aebischer, 2008). LV vectors have been shown to 
direct long-lasting expression of a number of transgenes in the brain (Lundberg et al., 2008) 
including in neurons in the rat SN (Deglon et al., 2000). AAV vectors are considered to be 
the most appealing vectors for transgene expression in the CNS, due to their efficient 
neuronal transduction, their capacity to direct long-term transgene expression and their 
safety profile (Kaplitt et al., 2007; Mandel et al., 2006; McCown, 2005). The early AAV 
vectors were based on AAV serotype 2 (Kaplitt et al., 1994; Peel & Klein, 2000), but 
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subsequent vectors have been generated with novel serotypes that differ in their tissue and 
cellular tropism (Wu, Asokan, & Samulski, 2006). 
So far, three studies engaged in exploring the possibility of AAV transgene expression in the 
mouse SN. In two studies only AAV vectors based on serotype 2 were used inducing either 
alpha-synuclein (St Martin et al., 2007) or dual leucine zipper kinase (Chen et al., 2008) 
expression in the DAergic neurons of the mouse SN. In the third study AAV serotypes 1, 2, 5, 7 
and 8 were injected into the mouse SN and compared for their tropism for DAergic neurons 
(Taymans et al., 2007). Although, AAV1 and 5 displayed the most promising transduction 
rates, this data was qualitatively assessed.  In contrast, the rat dopaminergic system has been 
studied much more extensively with five studies investigating the performance of various 
AAV serotypes tropism.  These studies compared the levels of GFP expression in the rat SN 
after injection of AAV vector serotype 1, 2 and 5 (Burger et al., 2004; Paterna, Feldon, & Bueler, 
2004), AAV8 (Klein et al., 2006; McFarland, Lee, Hyman, & McLean, 2009), and AAV9 and 10 
(Klein, Dayton, Tatom, Diaczynsky, & Salvatore, 2008). A general conclusion for all these 
studies establishes AAV2 as the lowest transducing vector of dopaminergic neurons in the rat 
SN. Finally and most recently, one AAV serotype study has been performed in primate CNS, 
where AAV1 to 6 viral vectors were injected into the SN (Markakis et al., 2010). In the primate 
AAV5 displays the most promising transduction of neurons in this area.   
In the following study, we have compared multiple AAV serotypes for transduction of 
mouse and rat mesencephalic DAergic neurons. AAV vectors were developed to contain 
either a cytomegalovirus (CMV) promoter or the human synapsin 1 (SYN) promoter. We 
demonstrate that the synapsin promoter leads to higher nigral transduction compared to 
the CMV promoter in mice. Additionally we also show that in our setting, AAV serotype 
5 and 7 give the highest transduction rate of DAergic neurons in the mouse SN, where as 
rat SN can be equally well transduced with all serotypes tested. We compare our study 
with the published data and underline the differences in the methodology and outcome 
measures.  
2. Methods 
2.1 AAV constructs and production 
Lentiviral vectors were produced as described before (Hendriks, Eggers, Verhaagen, & Boer, 
2007). Two plasmids, designated pTRCGw and pTRUF20B-SEW, were used for the production 
of AAV. The pTRCGW plasmid contained inverted terminal repeats of AAV2 flanking a 
cytomegalovirus (CMV) promoter driving expression of GFP, a woodchuck hepatitis virus 
posttranscriptional regulatory element (WPRE), and a polyadenylation signal (Ruitenberg, 
Eggers, Boer, & Verhaagen, 2002). The second plasmid, designated pTRUF20B-SEW, was a 
generous gift from Prof. Deniz Kirik (Lund University, Sweden). This plasmid also contained 
two inverted terminal repeats of AAV2 flanking a human synapsin 1 (SYN) promoter driving 
expression of GFP, a WPRE, and a polyadenylation signal. For the production of different 
serotypes helper plasmids were used provided by J.A. Kleinschmidt (AAV1 to 6) (Grimm, 
Kay, & Kleinschmidt, 2003) and J.M. Wilson (AAV7 and 8) (Gao et al., 2002). For each serotype 
eight 15 cm petridishes containing 1x107 HEK293T cells were transfected with the use of 
polyethylenimine (PEI, MW25000; Polysciences Inc., Warrington, PA, USA). Cells were grown 
in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% fetal calf serum (FCS) and 
1% penicillin/streptomycin (GIBCO-Invitrogen Corp, New York, NY, USA). pTRCGW or 
pTRUF20B-SEW AAV plasmids were cotransfected with packaging plasmids in different 
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ratios as follows: AAV1 to 6 in a ratio of AAV plasmid over capsid plasmid 1:3 with a total 
amount of 50µg of DNA per plate, and AAV7 and 8 in a ratio of 1:2:2 of AAV plasmid over 
helper plasmid pAd∆F6 and capsid plasmid with total amount of 62.5µg of DNA per plate. 
Two days after the transfection cells were harvested in D-phosphate buffered saline (PBS) 
(Gibco) containing 10µg/ml DNAseI (Roche Diagnostics GmbH, Mannheim, Germany) and 
incubated for 1 hour at 37°C. Cells were lysed by three freeze-thaw cycles, spun down 30 min 
at 4000rpm and crude lysate was collected. Virus was purified by the iodixanol gradient ultra-
centrifugation method (Hermens et al., 1999; Zolotukhin et al., 1999), diluted in D-PBS/5% 
sucrose and concentrated using Amicon 100kDA MWCO Ultra-15 device (Millipore, Billerica, 
MA, USA). All AAV vectors were stored at -80°C until use. Titers were determined by 
repeated quantitative PCR for viral genomic copies extracted from DNAse-treated viral 
particles using WPRE directed primers (forward: CAGGTGTATTGCCACAAGACAAA and 
reverse: TGCACAGGTGAAGACCAAGCAA). Table 1 provides an overview of all viral stocks 
and their titers used in this study.  
 
 
Table 1. Viral vectors, titers and injection coordinates. All AAV batches have a similar range 
of titer with an exception of AAV5-SYN, which has a significantly higher titer than the other 
AAV-SYN viruses (after multiple testing, P<0.001, one way ANOVA). The injection 
coordinates are indicated for mice and rats respectively. Abbreviations: CMV- 
cytomegalovirus, SYN-synapsin, GCs/ml- genomic copies per milliliter, AP- Anterior 
Posterior, L- lateral, and VD- Ventral Dorsal distances from bregma. 
2.2 Experimental animals and surgical procedures 
A total of 43 male C57BL/6 mice weighing 20-25g and 16 female Sprague-Dawley rats 
weighing 200-250g were used (Harlan, Zeist, The Netherlands). Animals were housed with 
food and water ad libitum, with 12 hour light and dark cycles. All the experimental 
procedures and postoperative care was carried out in accordance with the local animal 
experimental ethical committee. 
The viral injections were carried out with the use of glass capillaries (0.78/1.0mm 
internal/external diameter; Harvard Apparatus, Holliston, MA, USA) with an 80µm tip. 
These glass capillaries were connected to Portex polyethylene tubing in turn connected to a 
Hamilton syringe fixed in a micro-infusion pump (PHD2000, Harvard Apparatus). The 
system was filled with water and a target volume of 1µl and an infusion rate of 0.2µl/min 
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was set for mice injections and target volume of 2µl and an infusion rate of 0.4 µl/min for 
rats. The glass needles were mounted on a stereotactic device (David Kopf Instruments, 
Tujunga, CA, USA). A total of 1.1µl of virus was loaded for mice and 2.3 µl for rats for each 
injection separately.  
Mice were intraperitoneally (IP) injected with FFM mix made of Hypnorm (0.1 mg/kg 
Fentanyl citrate/ 3.3 mg/kg Fluanisone HCl, Janssen Pharmaceuticals) and Dormicum (8.3 
mg/kg Midazolam, Roche) and placed into a stereotactic device where they were fixed and 
the skull was exposed. The skull was leveled based on the heights of bregma, lambda and 
two additional and very crucial lateral measurements of 2.0 mm from bregma. The injection 
coordinates were calculated from bregma with anterior posterior (AP) being -2.8 mm and 
lateral (L) -1.3 mm. Ventral dorsal (VD) coordinate was measured from the dura of either -
4.1, -4.2 or -4.3 mm depending on the viral injection (see table 1). Subsequently, the needle 
was lowered into the brain 0.1 mm below the VD coordinate and retracted back up to the 
correct level. After the infusion, the needle was left in place for 5min before retraction.  
Rats were anesthetized by intramuscular injection of 0.08ml/100g of Hypnorm and 
mounted in the stereotact. The skull level was controlled by measurement of bregma and 
lambda. 2µl of each AAV virus was injected at the following coordinates with VD being 
measured from dura: AP -5.2, L -2.0, and VD 7.2 (Ulusoy, Sahin, Bjorklund, Aebischer, & 
Kirik, 2009).   
All of the animals recovered on a heating pad at 37°C and were allowed to survive for 4 
weeks post surgery after which they were sacrificed by an IP overdose with Pentobarbital 
(50mg/µl) and transcardially perfused with 0.9% saline followed by 4% paraformaldehyde 
(PFA, Sigma-Aldrich Co., St. Louis, MO, USA) in PBS pH 7.4. The brains were further post-
fixed overnight and 4 series of 30µm thick coronal sections were cut on a vibratome. The 
sections were stored free-floating at 4°C in 1% PFA in PBS pH 7.6.  
2.3 Immunohistochemistry and histological quantification 
All immunohistochemical (IHC) stainings were performed on free-floating sections. Prior to 
the staining, one series of sections was pre-blocked in 1x tris buffered saline (TBS) (Sigma) 
with 2.5% fetal calf serum (FCS) and 0.2% Triton-X (Sigma) for 1 hour at room temperature. 
Sections were then incubated with anti-tyrosine hydroxilase (TH) rabbit polyclonal antibody 
(Institute Jacques Boy SA, Reims, France) at 1:1000 dilution in blocking buffer and anti-GFP 
(Millipore) chicken monoclonal antibody at 1:1000 for 1 hour at room temperature followed 
by overnight incubation at 4°C. Secondary goat anti-rabbit antibody Alexa 594 (1:400, 
Invitrogen, Carlsbad, CA, USA) was used for the detection of the TH antibody and donkey 
anti-chicken Alexa 488 (1:400, Invitrogen) for the detection of the GFP antibody. These 
antibodies were incubated for 1 hour at room temperature. Sections were then mounted on 
chrome-aluin and gelatin coated glass slides. 
Images were acquired with an Axioplan microscope (Zeiss, Sliedrecht, The Netherlands). 
Images for quantification of the transduced neurons of the SN were taken at 10x 
magnification for mice and 5x magnification for rats with fixed exposure times for both TH 
and GFP signal. The sections of the striatum area were photographed at 2.5x magnification 
also with fixed exposure times for both TH and GFP fluorescent signal. 
ImagePro Plus Fluorviewer software (Media cybernetics, Bethesda, MD, USA) was used for 
the SN transduction quantification. All TH-positive neurons were manually counted in a 
single-blinded setup. Furthermore, TH and GFP colocalization was assessed using cellular 
morphology and fluorescent intensity parameters. For each section the percentage of GFP-
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positive and TH-positive cells was determined, and all values from all of the sections were 
averaged to give the total percentage of colocalized cells in the whole structure. In the AAV-
SYN comparison study one animal in AAV8 group, which the injection had missed the SN 
structure, was excluded from further statistics unless specified. Caudate quantification was 
performed with the use of ImagePro Plus Measure Threshold macro. The striatal areas in both 
hemispheres were outlined based on the TH expression in the striatal fibers. The average GFP 
background signal measured in cortex areas in both hemispheres was subtracted from each 
ipsilateral striatum signal. Next, the recalculated intensity from the non-injected striatum was 
subtracted from the injected side. Finally, this average intensity value in the injected striatum 
was multiplied by the size of the area resulting in total GFP intensity of the measured area. 
3. All AAV serotype vectors with the CMV promoter direct poor transgene 
expression in DAergic neurons of the mouse SN 
Vectors based on AAV serotypes 1, 2, 5, 7, 8 and LV that contained the CMV-GFP expression 
cassette were injected into the mouse SN. Four weeks after the injection, the number of TH-
positive neurons expressing GFP was quantified. All AAV serotypes and the LV vector 
showed very low numbers of transduced TH-positive neurons (Figure 1B). AAV7 directs the 
highest transduction rate with 8% of the TH-positive SN cells expressing GFP. Most of the 
serotypes, with the exception of AAV2, showed high rates of cellular transduction in and 
around the SN, but the transduced neurons were TH-negative (Figure 1A). AAV1 and LV 
also transduced glial cells particularly in the area directly surrounding the injection site 
(data not shown). Glial transduction has not been observed with any other AAV serotypes.   
Three groups have reported on AAV-mediated gene transfer to the mouse SN (Chen et al., 
2008; St Martin et al., 2007; Taymans et al., 2007). Experimental details, including the 
serotype and promoter used in these studies are summarized in Table 2.  
 
 
Table 2. Summary of literature reports using AAV vectors for gene transfer in mouse SN.  
A comparative analysis of AAV1, 2, 5, 7 and 8 showed efficient transduction of cells in the 
SN area (Taymans et al., 2007).  AAV 1 and 5 showed robust GFP expression in the fibers of 
the striatum. In contrast AAV7 and 8 directed only low GFP levels in this projection area of 
the SN DAergic neurons. Additionally, a few GFP positive cells were observed in the 
striatum in all of the serotypes. Consistent with our observations, AAV2 showed poor 
transgene expression in the SN. The efficiency of AAV-CMV driven GFP expression was 
assessed qualitatively and no specification of the DAergic lineage of the transduced cells 
was performed. We have also found high numbers of GFP expressing cells with AAV-CMV 
vectors in and around the SN, however, quantification of the TH-positive GFP-labeled cells 
revealed very low numbers of GFP expressing DAergic neurons in the SN (Figure 1).  
www.intechopen.com
  
Viral Gene Therapy 
 
210 
 
Fig. 1. AAV-CMV-mediated GFP expression in the mouse Substantia Nigra. A. Confocal Z-
stack image of an immunohistochemical staining of the mouse SN showing GFP transgene 
expression in a small number of dopaminergic neurons identified by TH staining (arrows 
indicate the double labeled cells) but also in non-dopaminergic neurons (arrowheads) after 
AAV6-CMV injection. TH neurons are shown in red, GFP is shown in green. The scale bar 
indicates 50µm. B. Quantification of transduced DAergic neurons in the mouse SN (n=3) 
using LV-CMV-GFP and AAV-CMV-GFP viral vectors. The bars represent the percentage of 
TH positive neurons in the SN expressing GFP. AAV7 shows the highest transduction of 8% 
of DAergic neurons in the SN. Error bars indicate the SEM. 
The other two studies, performing AAV mediated gene transfer in mouse SN used only 
serotype 2. In the first study, injection of AAV2 into the SN showed between 10 and 80% of 
TH-positive neurons that express GFP in individual sections (St Martin et al., 2007). In the 
second study AAV2 was injected into the posterior SN, which resulted in transduction of 
71.1±6.0% of TH-positive neurons (Chen et al., 2008). The number of GFP transduced cells in 
both of these studies is much higher compared to our study, where AAV2-CMV led to the 
lowest transduction rate of SN neurons. Although both studies used slightly different 
injection coordinates than we did, it is unlikely that this caused significant differences in 
AAV2 transduction efficiencies. The most likely explanation for this difference is the use of 
the chicken β-actin (CBA) promoter, a promoter known to drive stronger and more 
persistent expression in several population of neurons (Fitzsimons, Bland, & During, 2002). 
Unfortunately there were no other serotypes used in these studies.  
4. AAV vectors that harbor the synapsin promoter direct high-level transgene 
expression in dopaminergic neurons of the mouse SN 
Based on our results and the available literature, the CMV promoter appears to direct less 
efficient transgene expression in different cell types, including striatal neurons (Jakobsson, 
Ericson, Jansson, Bjork, & Lundberg, 2003), cochlea cells (Liu et al., 2007), human embryonic 
stem cells (Orban et al., 2009) and finally rat SN neurons (Paterna, Moccetti, Mura, Feldon, & 
Bueler, 2000; Wang et al., 2005). Therefore we conclude that the CMV promoter leads to a 
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Fig. 2. GFP expression in AAV-SYN injected mouse SN. GFP stained (green) and TH stained 
(red) neurons are visualized in confocal images. Arrows point to examples of GFP positive 
and TH positive cells in all viral serotypes. A. AAV5-SYN-GFP; B. AAV6-SYN-GFP;  
C. AAV7-SYN-GFP; and D. AAV8-SYN-GFP. The scale of 50µm is represented by a bar in 
panel A. 
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limited transduction in the mouse SN and may not be suitable to drive viral vector-
mediated transgene expression in the DAergic neurons of the mouse SN. The human 
synapsin 1 promoter, on the other hand, has been shown to be an excellent neuron specific 
promoter in co-cultured primary hippocampal neurons isolated from embryonic brain 
(Kugler, Lingor, Scholl, Zolotukhin, & Bahr, 2003), in primary dorsal root ganglion cultures 
(Sims et al., 2008) and in vivo following injection of an adenoviral vector in rat brain, 
including the SN (Hermening, Kugler, Bahr, & Isenmann, 2006; Kugler, Kilic, & Bahr, 2003; 
Kugler et al., 2003). We therefore produced 4 AAV vectors (AAV5, 6, 7 and 8) that harbored 
a GFP reporter gene under the human synapsin 1 promoter. The performance of these AAV 
vectors was tested in mice and rats after injection in the SN. 
4.1 AAV-synapsin-GFP drives transgene expression in tyrosine hydroxylase positive 
neurons 
Vectors based on AAV serotypes 5, 6, 7 and 8 that contained a SYN-GFP expression cassette 
were injected in the SN in the same fashion as the AAV-CMV-GFP viral vectors. All 
serotypes directed GFP expression in neurons throughout the midbrain, including the SN. 
AAV7 injected mice showed the most widespread viral transduction with GFP-positive 
neurons in multiple midbrain areas (data not shown).  
Subsequently, we specifically investigated the transduction efficiency of DAergic neurons of 
the SN. Immunohistochemical staining showed that all serotypes transduce TH positive 
neurons in the mouse SN (Figure 2). Interestingly, the level of GFP expression in the 
individual TH positive cells appears to be lower than in other TH-negative neurons in the 
SN area. This was also observed following transduction with AAV-CMV vectors.  In 
addition, large numbers of GFP positive fibers were observed in the SN. Based on cellular 
morphology, no other cell types expressed GFP. This indicates that the AAV-SYN-GFP 
construct drives neuron-specific expression.  
4.2 AAV5 and AAV7 mediate the highest transduction of TH positive neurons in the 
mouse SN 
Quantification of the number of TH-positive and GFP-positive neurons in the SN 
demonstrated a much higher proportion of double labeled neurons with all AAV-SYN 
vectors compared to the AAV-CMV vectors. AAV5 and AAV7 lead to significantly higher 
percentage of the GFP labeled DAergic neurons compared to AAV6 and AAV8. These two 
serotypes directed GFP expression in 76-80%of TH-positive neurons (Figure 3A). The 
homogeneous distribution of the TH and GFP-positive neurons from the posterior to the 
anterior side of the SN corroborates the superiority of AAV5 and AAV7 compared to 
AAV6 and AAV8 at each anatomical level (figure 3B, for more details see supplementary 
figure 1).  
In conclusion, AAV5-SYN and AAV7-SYN are the most effective vectors for transduction of 
DAergic neurons in mouse SN. Interestingly, even though AAV5 had a significantly higher 
titer in comparison to AAV7, it transduces a comparable number of DAergic neurons 
throughout the SN. In contrast, AAV8 injected animals, apart from a relatively low total 
percentage of TH and GFP-positive neurons, display a decrease in the number of these 
neurons in the anterior portion of the SN. AAV6 shows quite poor transduction efficiency 
throughout the SN. This is in accordance with the relative low overall percentage of TH-
positive neurons that express GFP (Figure 3A).  
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Fig. 3. AAV-SYN-GFP transduction of mouse SN. A. Quantification of TH positive (TH+) 
and GFP positive (GFP+) neurons in mouse SN transduced with different AAV serotypes. 
In the AAV5 and AAV7 groups, almost 80% of TH+ neurons express GFP, which is 
significantly higher than the AAV6 group where < 20% of the DAergic neurons are GFP 
positive (P<0.001), and the AAV8 group where 35% of the DAergic neurons express GFP 
(P<0.01). B. Quantification of GFP expressing TH+ cells per serotype in SN serial sections 
arranged according to the Allan Brain Atlas TH in situ hybridization (Lein et al., 2007) 
with 1 being most posterior and 8 being the most anterior part of the SN (supplementary 
figure 1). Throughout the groups there was no statistical significant difference between 
AAV5 and AAV7, however in section groups 2, 4, 5, 6 and 7 AAV7 showed significantly 
higher average of GFP+/TH+ cells than the other two serotypes (* P < 0.05, ** P < 0.01, *** 
P < 0.001), where as in section 3 only comparing to AAV6 (P < 0.01). AAV5 showed a 
significantly higher GFP expression in comparison to AAV6 and AAV8 serotypes in 
section groups 4, 5, 6, 7 and 8 and in section 2 and 3 to AAV6 only. AAV8 shows 
significantly higher GFP expression to AAV6 in group 3 and 4 (* P < 0.05, **P < 0.01,  
*** P < 0.001). 
4.3 AAV7 shows the most GFP positive fibers ascending through the nigrostriatal 
tract 
The DAergic neurons of the substantia nigra anatomically project to the striatum creating 
the nigral-striatal pathway. Accordingly, when the DAergic neurons in the substantia 
nigra are transduced their fibers in the striatum are expected to be GFP positive. To 
investigate this relationship, we have quantified the intensity of GFP fluorescent signal in 
the mouse striatum and compared this to the effectiveness of the AAV serotypes to target 
the DAergic neurons in the SN (Figure 4). While AAV5-SYN-GFP and AAV7-SYN-GFP 
display a high fluorescence intensity of GFP, AAV6-SYN-GFP and AAV8-SYN-GFP show 
a low level of GFP expression in the striatum. Furthermore, AAV7-SYN directs 
significantly higher levels of GFP expression in the striatum compared to AAV5-SYN 
(Figure 4 E). Moreover, we have found a significant correlation between the transduction 
efficiency of the SN and the labeling intensity of the fibers in the striatum (Figure 4F).  
This corroborates the superiority of the AAV7 and AAV5 serotypes in transducing 
DAergic neurons in the mouse SN. 
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Fig. 4. GFP expression in the mouse striatum after SN AAV transduction. A-D. Mouse 
striatal sections stained with anti-TH (red) and-GFP (green) antibody transduced with 
different AAV serotype. The scale bar represents 1mm. E. Quantification of GFP fluorescent 
intensity in all AAV-SYN serotypes. Each striatal section was measured for GFP intensity 
and corrected for the measured area (gray level*mm2). Statistical analysis indicates AAV7-
SYN-GFP result in the highest GFP expression in the striatum, with AAV5 inducing the 
second best expression (*P<0.05, **P< 0.01 and ***P<0.001). F. The percentage of TH+ 
neurons expressing GFP in the SN and the level of GFP fluorescence in the striatum are 
significantly correlated (Pearson correlation, R2=0.729, P<0.001). Each individual animal 
belonging to a specific AAV serotype injection group is depicted by different marker 
described in the figure legend. Animal with missed injection in AAV8-SYN group (as 
described in Methods section) was also included in this analysis. 
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Taken together, these observations demonstrate that AAV7-SYN is the best vector for the 
transduction of TH-positive neurons of mouse SN among the tested serotypes regarding the 
specificity and the transduction rate. Although both AAV5 and AAV7 effectively 
transduced large numbers of TH-positive neurons in the SN, AAV7 showed significantly 
higher GFP expression in the striatum. Injection of AAV7-SYN also resulted in a substantial 
transduction of other neurons in the midbrain. This indicates that AAV7 spreads further 
than other serotypes and/or has a more ubiquitous neuronal tropism in the mouse brain. It 
would be worthwhile to investigate whether it is possible to more specifically target only 
DAergic neurons in the SN by e.g. lowering the volume of the viral vector solution that is 
injected into the SN. Finally, we have not seen any signs of toxicity following the injection of 
high titer AAV vectors in the mouse brain.  
5. All AAV-vectors harboring the synapsin promoter direct similar level of 
transgene expression in the rat SN and the striatum 
5.1 All AAV-synapsin serotypes show similar GFP expression throughout the rat SN 
Female Sprague-Dawley rats were injected with AAV-SYN-GFP viral vectors 5, 6, 7 and  
8 into the SN. The viral stocks used were the same as in mouse SN injections. To estimate the 
transduction efficiency, the TH-positive and GFP-positive neurons of the SN were 
quantified in the same fashion as described in the mouse study. All AAV serotypes showed 
similar numbers of GFP-positive neurons in the rat SN (Figure 5A) with no significant  
 
 
Fig. 5. AAV-SYN-GFP transduction of rat SN. A. Quantification of TH positive (TH+) and GFP 
positive (GFP+) neurons in rat SN transduced by different AAV serotypes. All serotypes 
showed similar GFP expression in about 30-40%of DAergic neurons. B. Quantification of GFP 
expressing TH-positive cells per serotype in the SN serial sections arranged in posterior-distal 
direction accordingly to the ‘The rat brain atlas’ by Paxinos and Watson (2007) (arrangement 
was based on the stereotact anatomical slides and adjacent Acetylcholinesterase (AChE) 
stainings with 1 being most posterior area and 8 being the most anterior area of the SN 
(supplementary figure 2)). All of the serotypes show similar GFP distribution within the SN 
structure with two exceptions: section 1 shows AAV5 expressing significantly higher amount 
of GFP + in TH+ cells comparing to AAV7 (* P < 0.05) and section 8 where AAV7 has greater 
amount of GFP+ DAergic cells than AAV8 (* P < 0.05). 
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Fig. 6. GFP expression in the rat striatum after SN AAV injection. A-D. Rat striatal sections 
stained with anti-TH (red) and-GFP (green) antibodies. The scale bar represents 1mm. E. 
GFP fluorescent intensity quantification in the striatum for all AAV-SYN serotypes. Whole 
striatum was cut, stained and each section was measured for GFP intensity and corrected for 
the measured area (gray level*mm2). Statistical analysis shows no differences in GFP 
expression levels between the different AAV serotypes. F. The percentage of TH+ neurons 
expressing GFP in the SN and the level of the GFP fluorescence in the striatum are 
significantly correlated (Pearson correlation R2=0.357, P<0.05). Each individual animal 
belonging to a specific AAV serotype injection group is depicted by different marker 
described in the figure legend. 
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differences between the serotypes. For AAV5 and AAV7 the proportion of transduced TH-
positive neurons is lower in the rat SN compared to the mouse SN. AAV6 directed 
transgene expression in a higher proportion of DAergic neurons in the rat SN (27%) than in 
mouse SN (16%), whereas AAV8 shows slightly higher number of GFP-positive neurons in 
the mouse SN (36%). These results suggest differential AAV tropism for DAergic neurons in 
rats comparing to mice.   
Analysis of the distribution of the GFP-positive neurons within the SN also shows no major 
differences between the AAV serotypes (Figure 5B) except for two anatomical levels where 
AAV5 shows significantly higher amount of TH-positive and GFP-positive cells when 
compared to AAV7 in section 1, and AAV7 shows more GFP-positive DAergic neurons 
when compared to AAV8 in section 8. Although significant, these differences are not 
prominent enough to allow us to speculate on either of the serotype superiority in 
transducing rat DAergic neurons. 
5.3 All AAV-SYN serotypes show GFP expression in the fibers of the rat striatum  
As in the mouse study, we have quantified the intensity of GFP signal in the rat striatum to 
compare the effectiveness of AAV serotype transduction of the rat SN anatomical projection 
(Figure 6). All AAV serotypes showed similar, relatively high levels of GFP expression in 
the striatum (Figure 6E). A correlation analysis revealed a significant correlation between 
the numbers of TH and GFP-positive neurons and the levels of GFP expression in striatum 
(Figure 4F). This further supports that all AAV serotypes are equally effective in targeting 
rat substantia nigra DAergic neurons. In addition, we have observed a transduction of the 
globus pallidus fibers by AAV5 and AAV7 serotypes. This may suggest more spread of 
these viral vectors in the rat brain.   
5.4 AAV7 viral vector injection decreases the amount of TH-positive cells in the rat SN 
We observed a > 50% decrease of number of TH-positive neurons in rat SN after AAV7 
injection when compared to the non injected contra-lateral side of the structure (Figure 7). 
We also studied the expression of vesicular monoamine transporter-2 (VMAT2), another 
DAergic phenotype marker, and found its protein levels also strongly decreased in the 
injected SN (data not shown).  Interestingly, the number of TH-positive and GFP-positive 
neurons in the SN is not less than in the other serotypes (Figure 5) as well as the intensity of 
GFP-positive fibers in the striatum (Figure 6).  
6. Discussion and concluding remarks 
Targeted gene delivery to mesencephalic DAergic neurons can be a very valuable approach 
to study the molecular mechanisms that underlie the development and progression of PD. 
Gene delivery to DAergic neurons has also a potential to evolve into a new therapeutic 
strategy for PD. In this study we have compared the capacity of multiple AAV serotypes to 
deliver a reporter gene to DAergic neurons in the adult mouse and rat SN. We have 
quantified the transduction efficiency of AAV vectors harboring two different promoters: 
the CMV and human synapsin 1 (SYN) promoter. We have demonstrated that following 
stereotactic injection of vectors containing the SYN promoter, a large number of DAergic 
neurons express GFP in the mouse as well as the rat SN. AAV7 is the most effective serotype 
for transduction of mouse SN DAergic neurons. AAV5 also displayed high transduction 
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efficiency for TH-positive neurons, but the GFP expression levels in the striatum were 
consistently lower when compared to AAV7. In the rat, all AAV-SYN vectors efficiently 
transduced DAergic neurons in the SN. AAV vectors containing the CMV promoter directed 
expression only in a small proportion of TH-positive SN neurons in mice, thereby 
demonstrating superiority of the synapsin promoter in this specific neuronal subtype. 
Collectively, these observations are useful for future experiments that aim to study the 
function of specific genes in the mesencephalic DAergic system. 
 
 
Fig. 7. AAV7 decrease of TH immunohistochemical signal in rat SN. All of the images were 
obtained from the same brain section. A. and C. Rat SN injected with AAV7-SYN-GFP B. 
Contra-lateral non injected side of the rat SN.  Section was stained for TH (red), a nuclear 
marker Hoechst (blue) and GFP (green). The scale bar in panel C represents 0.5mm. D. 
Quantification of the TH positive neurons in the rat SN after AAV7 transduction. TH 
positive neurons were counted in both the AAV7 injected side of the SN and the contra-
lateral side in each section. One way ANOVA indicated a significant decrease of TH+ 
neurons in the AAV7 injected SN (** P < 0.01). 
So far, one study has compared five AAV serotypes (AAV 1, 2, 5, 7 and 8) for gene delivery 
to the mouse SN (Taymans et al., 2007). All vectors, except for AAV2, showed positive 
transduction of the SN area, with AAV1 and AAV5 implicating to direct highest levels of 
GFP in the striatal fibers. This study did not show quantifications of the numbers of GFP 
and TH-positive neurons and GFP expression in striatal fibers, and can therefore not be 
directly compared to our study.  
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For the rat SN, the four tested AAV serotypes directed equally efficient transduction in 
DAergic neurons. In comparison, AAV5 and AAV8 appear to display the most consistent 
transduction efficiencies in the literature (Klein et al., 2006; McFarland et al., 2009; Paterna et 
al., 2004). Additionally, AAV9 and AAV10 have also been tested and indicated to have 
higher tau expression in the SN area and higher TH neuronal loss evoked by tau expression 
comparing to AAV2 and AAV8 (Klein et al., 2008).  These observations in combination with 
our results indicate that multiple AAV serotypes share relatively high tropism for DAergic 
neurons of the rat SN.  
In the mouse SN, AAV vectors with the SYN promoter were superior to the AAV vectors 
containing the CMV promoter. In contrast, in the rat, a range of promoters have been used 
very successfully to direct the transgene expression in the DAergic neurons of the SN via an 
AAV vector including the CMV (McFarland et al., 2009), CBA (Burger et al., 2004; Klein et 
al., 2006; Paterna et al., 2004; Ulusoy et al., 2009), CMV/CBA hybrid (Klein et al., 2008) and 
PDGV (Paterna et al., 2000)) promoters. This suggests that for experiments in the rat the 
choice of the promoter is not as critical as it appears to be for the mouse.  
Following AAV7-SYN-GFP injection, a dramatic decline in TH and VMAT2 expression 
occurred in the DAergic neurons in the rat SN. Klein et al. also observed a decrease in the 
number of TH-positive cells following high titer AAV8-GFP application, but not after 
AAV8-empty vector. Moreover, following the application of lower AAV8-GFP viral titer, no 
decrease of TH signal was noted. Therefore the authors suggest that the high concentrations 
of GFP can be neurotoxic to the DAergic neurons of the rat SN (Klein et al., 2006). Ulusoy et 
al. also reported a neurotoxic effect of high titer AAV5-GFP viral vectors. In this study not 
only TH was diminished, but also the expression of VMAT2. In subsequent experiments 
with low titer AAV5-GFP injections this effect was not seen anymore (Ulusoy et al., 2009). 
We speculate that in our case, the high tropism of AAV7 for DAergic neurons induces more 
GFP expression, and as a consequence causes DAergic neurotoxicity. We do not see this 
effect on TH expression in mice SN after the AAV7 injection.  
As presented here, the specifications of the delivery vehicle can be crucial for successful and 
accurate cellular transduction. We have demonstrated that targeting SN in the mouse is 
difficult and could only be successfully achieved in our set up with AAV serotypes 7 and 5 
harboring the SYN promoter. In contrast targeting rat SN can be efficiently achieved by 
multiple AAV viral vectors. It is therefore necessary to determine the vector potential for 
each animal species before pursuing genetic manipulation in the DAergic system. This can 
also be valid for human clinical PD gene therapy studies. So far AAV2 has been the only 
vector injected into the human brain as a delivery vehicle for PD gene therapy (Kaplitt et al., 
2007; Marks, Jr. et al., 2010; Muramatsu et al., 2010). As discussed before, AAV2 seams to be 
the least efficient vector in the transduction of DAergic neurons in the rodent brain. 
Understandably human serotype studies are not possible, but primate studies may shed 
more light on the transduction efficiency of different delivery vehicles and can improve the 
efficiency of the gene therapies dramatically. One such study has recently indicated AAV5 
to be the most efficient in transducing neurons in the area of SN but also glial cells, whereas 
glial transduction by AAV5 is not observed in the rodent brain (Markakis et al., 2010). This 
clearly illustrates the differences between viral vector transduction preferences between 
animal species.   
Another major concern at the moment in the field of gene therapy is the specification of the 
target area. Two of the above mentioned clinical studies have targeted the putamen of PD 
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patients (Marks, Jr. et al., 2010; Muramatsu et al., 2010) and one the subthalamic nucleus 
(Kaplitt et al., 2007). Depending on the function of the target gene, the location of the target 
area is crucial for successful therapeutic application. It is therefore rational to apply gene 
therapy for dopamine synthesis enzymes such as AADC to the putamen to increase the 
dopamine production at that area to alleviate the motor-related clinical symptoms 
(Muramatsu et al., 2010). On the other hand, it may not be as beneficial to induce an expression 
of a neurotrophic factor in the area not significantly affected by neuronal death (Marks, Jr. et 
al., 2010). It was therefore extensively discussed and suggested for the future to target the SN 
DAergic neurons when applying pro-survival and regenerative therapeutic agents (Benabid, 
2010; Marks, Jr. et al., 2010). Concluding, it is therefore necessary to apply the right vectors in 
the specific animal species and target the appropriate area of interest, depending on the 
function of the expression gene, for the most effective targeted gene delivery.  
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8. Supplementary figures 
 
 
Supplementary Fig. 1. Quantitative overview of AAV-SYN-GFP transduction throughout 
the mouse SN in 4 different viral serotypes. A. The sorting of SN anatomical areas through 
section groups 1-8 is based on a TH in situ hybridization presented by the Allen Brain Atlas 
(Lein et al., 2007). Section group 1 is the most posterior group and section group 8 the most 
anterior. B-E. Quantification of SN AAV transduction throughout the structure in 4 different 
viral serotypes in individual animals. Values represent mean of all quantified sections 
belonging to the sorted section group and their SEM.   
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Supplementary Fig. 2. Quantitative overview of AAV-SYN-GFP transduction throughout 
the rat SN in 4 different viral serotypes. A. The sorting of SN anatomical areas through 
section groups 1-8 is based on the anatomical AChE stainings presented by ‘The rat brain 
atlas’ by Paxinos and Watson (2007). Section group 1 is the most posterior group and section 
group 8 the most anterior with indicated distances from the bregma. B-E. Quantification of 
SN AAV transduction throughout the structure in 4 different viral serotypes in individual 
animals. Values represent mean of all quantified sections belonging to the sorted section 
group and their SEM. 
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